Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Total Liabilities (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Total Liabilities for 12 consecutive years, with $71.8 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 33.91% year-over-year to $71.8 million; the TTM value through Mar 2026 reached $71.8 million, down 33.91%, while the annual FY2025 figure was $112.3 million, 16.73% down from the prior year.
  • Total Liabilities hit $71.8 million in Q1 2026 for Wave Life Sciences, down from $112.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $294.1 million in Q1 2023 and bottomed at $71.8 million in Q1 2026.
  • Average Total Liabilities over 5 years is $175.3 million, with a median of $178.2 million recorded in 2022.
  • Year-over-year, Total Liabilities surged 84.35% in 2023 and then plummeted 48.53% in 2025.
  • Wave Life Sciences' Total Liabilities stood at $183.6 million in 2022, then grew by 23.88% to $227.4 million in 2023, then plummeted by 40.73% to $134.8 million in 2024, then fell by 16.73% to $112.3 million in 2025, then tumbled by 36.03% to $71.8 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $71.8 million, $112.3 million, and $109.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.